Amid criticism for its handling of another Alzheimer’s drug, FDA will decide this week whether to approve lecanemab

A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.